Sikic / Rozencweig / Carter Bleomycin Chemotherapy

1. Auflage 2013
ISBN: 978-1-4832-6502-5
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 335 Seiten, Web PDF

Bleomycin Chemotherapy focuses on the clinical uses of bleomycin. Bleomycin, a group of glycopeptides isolated from Streptomyces verticillus, has a unique structure and mechanism of action among anticancer drugs. The drug's remarkable lack of bone marrow toxicity prompted its addition to myelosuppressive regimens and enabled treatment of patients with compromised hematopoietic function. Bleomycin is an integral component of one of the great triumphs of medical oncology-the curative treatment of metastatic testicular carcinomas. Similar curative potential has been demonstrated for bleomycin in combination with cisplatin and vinblastine in germ-cell cancers of the ovary. Bleomycin is included in several important treatment regimens for Hodgkin's disease and non-Hodgkin's lymphomas. The drug also has clinical activity against squamous carcinomas of various sites. These uses and other aspects, including the development of new bleomycin analogs, are discussed in the following chapters, which were first presented at a symposium jointly sponsored by the Northern California Cancer Program and Bristol Laboratories in San Francisco, California, 14-15 September 1984.

Autoren/Hrsg.

Sikic, Branimir Ivan

Rozencweig, Marcel

Carter, Stephen K.

Inhaltsverzeichnis

1;Front Cover;1
2;Bleomycin Chemotherapy;4
3;Copyright Page;5
4;Table of Contents;6
5;CONTRIBUTORS;14
6;PREFACE;20
7;Section I: INTRODUCTION;22
7.1;Chapter 1. BLEOMYCIN: MORE THAN A DECADE LATER;24
7.1.1;I. INTRODUCTION;24
7.1.2;II. TESTICULAR CANCER;25
7.1.3;III. HODGKIN'S DISEASE;33
7.1.4;IV. NON-HODGKIN'S LYMPHOMA;41
7.1.5;V. HEAD AND NECK CANCERS;45
7.1.6;VI. UTERINE CERVICAL CANCER;49
7.1.7;VII. CONCLUSION;53
7.1.8;REFERENCES;54
7.2;Chapter 2. CLINICAL PHARMACOLOGY OF BLEOMYCIN;58
7.2.1;I. PHARMACEUTICAL PROPERTIES;58
7.2.2;II. MECHANISM OF ACTION;59
7.2.3;III. PHARMACOKINETICS;60
7.2.4;IV. CLINICAL USE;62
7.2.5;REFERENCES;63
8;Section II: TESTICULAR AND OVARIAN CANCERS;66
8.1;Chapter 3. CHEMOTHERAPY OF TESTICULAR CARCINOMA: AN OVERVIEW;68
8.1.1;I. INTRODUCTION;68
8.1.2;II. CHEMOTHERAPY;68
8.1.3;III. PROGNOSTIC VARIABLES;73
8.1.4;IV. TOXICITY;74
8.1.5;V. CONCLUSION;77
8.1.6;REFERENCES;78
8.2;Chapter 4. THE MEMORIAL HOSPITAL EXPERIENCE IN THE MANAGEMENT OF TESTICULAR GERM-CELL TUMORS;80
8.2.1;I. INTRODUCTION;80
8.2.2;II. THE VAB II REGIMEN;81
8.2.3;III. THE VAB III REGIMEN;81
8.2.4;IV. VAB IV AND VAB V REGIMENS;82
8.2.5;V. THE VAB VI REGIMEN;83
8.2.6;VI. ADJUVANT SURGERY;85
8.2.7;VII. CONCLUSION;87
8.2.8;REFERENCES;88
8.3;Chapter 5. EFFECTIVE TREATMENT OF MALIGNANT OVARIAN GERM-CELL TUMORS WITH CISPLATIN, VINBLASTINE, AND BLEOMYCIN (PVB);90
8.3.1;I. INTRODUCTION;90
8.3.2;II. METHODS;91
8.3.3;III. RESULTS;92
8.3.4;IV. DISCUSSION;94
8.3.5;ACKNOWLEDGMENTS;96
8.3.6;REFERENCES;96
9;Section III: HEAD AND NECK CANCER;98
9.1;Chapter 6. THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HEAD AND NECK CANCER;100
9.1.1;I. INTRODUCTION;100
9.1.2;II. SALVAGE TREATMENT;101
9.1.3;III. PRIMARY TREATMENT;105
9.1.4;IV. PROGNOSTIC FACTORS;111
9.1.5;V. CONCLUSIONS;111
9.1.6;REFERENCES;112
9.2;Chapter 7. HEAD AND NECK CANCER: BLEOMYCIN PLUS RADIOTHERAPY;116
9.2.1;I. INTRODUCTION;116
9.2.2;II. RANDOMIZED STUDIES;117
9.2.3;III. NONRANDOMIZED STUDIES;121
9.2.4;IV. NORMAL TISSUE EFFECTS OF COMBINED TREATMENT;121
9.2.5;V. DISCUSSION;127
9.2.6;REFERENCES;127
9.3;Chapter 8. THE ROLE OF INDUCTION CHEMOTHERAPY IN COMBINED-MODALITY TREATMENT PROGRAMS;130
9.3.1;I. INTRODUCTION;130
9.3.2;II. EFFECT ON TREATMENT AND SURVIVAL;131
9.3.3;III. TESTICULAR CANCER;132
9.3.4;IV. OSTEOSARCOMA;132
9.3.5;V. HEAD AND NECK CANCER;133
9.3.6;VI. DISCUSSION;133
9.3.7;VII. SUMMARY;134
9.3.8;ACKNOWLEDGMENT;135
9.3.9;REFERENCES;135
9.4;Chapter 9. INDUCTION CHEMOTHERAPY IN THE TREATMENT OF HEAD AND NECK CANCER: SUNY BUFFALO AND VAMC EXPERIENCE;138
9.4.1;I. INTRODUCTION;138
9.4.2;II. METHODS;139
9.4.3;III. RESULTS;140
9.4.4;IV. DISCUSSION;142
9.4.5;V. CONCLUSION;144
9.4.6;REFERENCES;144
10;Section IV: THE MALIGNANT LYMPHOMAS;146
10.1;Chapter 10. HODGKIN'S DISEASE: AN OVERVIEW AND ABVD STUDIES IN MILAN;148
10.1.1;I. INTRODUCTION;148
10.1.2;II. MOPP VERSUS ABVD;149
10.1.3;III. SALVAGE TREATMENT;151
10.1.4;IV. CYCLIC MOPP/ABVD;153
10.1.5;V. CONCLUSION;155
10.1.6;REFERENCES;155
10.2;Chapter 11. BLEOMYCIN IN COMBINATION WITH MOPP IN THE MANAGEMENT OF ADVANCED HODGKIN'S DISEASE: A SOUTHWEST ONCOLOGY GROUP EXPERIENCE;158
10.2.1;I. INTRODUCTION;158
10.2.2;II. PATIENT AND METHODS;159
10.2.3;III. RESULTS;163
10.2.4;IV. DISCUSSION;170
10.2.5;REFERENCES;174
10.3;Chapter 12. COMBINED-MODALITY STUDIES IN THE TREATMENT OF HODGKIN'S DISEASE;176
10.3.1;I. BACKGROUND;176
10.3.2;II. PROSPECTIVE CLINICAL TRIALS;177
10.3.3;III. COMBINED-MODALITY THERAPY IN PEDIATRIC HODGKIN'S DISEASE;186
10.3.4;IV. FUTURE DIRECTIONS;187
10.3.5;REFERENCES;188
10.4;Chapter 13. THE NON-HODGKIN'S LYMPHOMAS: AN OVERVIEW;190
10.4.1;I. LOW-GRADE LYMPHOMAS;191
10.4.2;II. INTERMEDIATE-GRADE LYMPHOMAS;194
10.4.3;III. HIGH-GRADE LYMPHOMAS;197
10.4.4;IV. FUTURE DIRECTIONS;198
10.4.5;REFERENCES;199
10.5;Chapter 14. NON-HODGKIN'S LYMPHOMAS: MILAN STUDIES;202
10.5.1;I. INTRODUCTION;202
10.5.2;II. COMBINED-MODALITY THERAPY FOR STAGE I TO STAGE II DISEASE;203
10.5.3;III. ALTERNATING CHEMOTHERAPY IN STAGE III TO STAGE IV DISEASE;205
10.5.4;IV. CONCLUSION;206
10.5.5;REFERENCES;206
10.6;Chapter 15. BACOP AND RELATED STUDIES IN NON-HODGKIN'S LYMPHOMA;208
10.6.1;I. SINGLE-AGENT BLEOMYCIN;208
10.6.2;II. BLEOMYCIN IN CHEMOTHERAPY COMBINATIONS;210
10.6.3;III. FOUR- AND FIVE-DRUG REGIMENS;210
10.6.4;IV. THERAPEUTIC PROGRAMS USING CONTINUOUS-INFUSION BLEOMYCIN;216
10.6.5;V. NEW INTENSIVE-TREATMENT MULTIDRUG REGIMENS;217
10.6.6;REFERENCES;219
11;Section V: NON—SMALL-CELL LUNG CANCER;222
11.1;Chapter 16. A REASSESSMENT OF BLEOMYCIN IN LUNG CANCER AND OTHER INTRATHORACIC NEOPLASMS;224
11.1.1;I. SYSTEMIC THERAPY OF LUNG CANCER;225
11.1.2;II. LOCALLY DIRECTED THERAPY;231
11.1.3;III. ROLE IN TREATING MESOTHELIOMA;232
11.1.4;IV. FUTURE DIRECTIONS;233
11.1.5;REFERENCES;234
11.2;Chapter 17. NON–SMALL-CELL LUNG CANCER: BLEOMYCIN PLUS ETOPOSIDE AND CISPLATIN;236
11.2.1;I. INTRODUCTION;237
11.2.2;II. PATIENTS AND METHODS;237
11.2.3;III. RESULTS;238
11.2.4;IV. DISCUSSION;244
11.2.5;REFERENCES;244
12;Section VI: CERVICAL CANCER;246
12.1;Chapter 18. CERVICAL CANCER: BLEOMYCIN STUDIES—AN OVERVIEW;248
12.1.1;I. INTRODUCTION;248
12.1.2;II. SINGLE-AGENT CHEMOTHERAPY;249
12.1.3;III. COMBINATION CHEMOTHERAPY INCLUDING BLEOMYCIN;253
12.1.4;REFERENCES;258
12.2;Chapter 19. BLEOMYCIN IN CERVICAL CARCINOMA: PROTOCOLS OF THE NORTHERN CALIFORNIA ONCOLOGY GROUP;260
12.2.1;I. INTRODUCTION;260
12.2.2;II. NCOG PROTOCOL 5C81;261
12.2.3;III. NCOG PROTOCOL 5C91;262
12.2.4;IV. DISCUSSION;263
12.2.5;REFERENCES;265
13;Section VII: PULMONARY TOXICITY;266
13.1;Chapter 20. PULMONARY TOXICITY OF BLEOMYCIN;268
13.1.1;I. INCIDENCE AND RISK FACTORS;268
13.1.2;II. CLINICAL FEATURES;269
13.1.3;III. PATHOGENESIS AND HISTOPATHOLOGY;270
13.1.4;IV. CLINICAL MANAGEMENT;272
13.1.5;V. FUTURE DIRECTIONS;273
13.1.6;REFERENCES;274
14;Section VIII: OTHER USES;276
14.1;Chapter 21. BLEOMYCIN: THE SEARCH FOR OTHER INDICATIONS;278
14.1.1;I. SINGLE-AGENT ACTIVITY OF BLEOMYCIN;279
14.1.2;II. SQUAMOUS-CELL CARCINOMAS;279
14.1.3;III. PRIMARY BRAIN TUMORS;285
14.1.4;IV. SUPERFICIAL BLADDER TUMORS;286
14.1.5;V. KAPOSI'S SARCOMA;287
14.1.6;VI. INTRACAVITARY THERAPY;287
14.1.7;VII. RECOMMENDATIONS FOR FUTURE STUDIES;289
14.1.8;VIII. BLEOMYCIN IN COMBINATION THERAPY;290
14.1.9;REFERENCES;292
15;Section IX: NEW BLEOMYCINS;296
15.1;Chapter 22. PEPLOMYCIN AND TALLYSOMYCIN S10b: TWO BLEOMYCIN ANALOGS;298
15.1.1;I. INTRODUCTION;298
15.1.2;II. CHEMISTRY;299
15.1.3;III. ANTITUMOR SCREENING ACTIVITY;300
15.1.4;IV. MECHANISMS OF ACTION;302
15.1.5;V. PRECLINICAL TOXICOLOGY;303
15.1.6;VI. PHARMACOLOGY;304
15.1.7;VII. CLINICAL STUDIES;304
15.1.8;VIII. CONCLUSION;307
15.1.9;REFERENCES;307
15.2;Chapter 23. NEW ANALOGS AND DERIVATIVES OF BLEOMYCIN;310
15.2.1;I. TOTAL SYNTHESIS OF BLEOMYCIN AND PREPARATION OF BLEOMYCIN ANALOGS;312
15.2.2;II. PREPARATION OF NEW BLEOMYCINS AND THEIR DERIVATIVES;313
15.2.3;III. SCREENING OF DERIVATIVES FOR CLINICAL STUDY;315
15.2.4;IV. LIBLOMYCIN;316
15.2.5;REFERENCES;321
16;Section .: SUMMARY AND PROSPECTS;324
16.1;Chapter 24. BLEOMYCIN: FUTURE PROSPECTS;326
16.1.1;I. INTRODUCTION;326
16.1.2;II. COMBINATION CHEMOTHERAPY;328
16.1.3;III. BLEOMYCIN AND RADIOTHERAPY;329
16.1.4;IV. FUTURE DIRECTIONS;329
16.1.5;V. SUMMARY;331
16.1.6;ACKNOWLEDGMENT;331
16.1.7;REFERENCES;331
16.2;Chapter 25. BLEOMYCIN IN CHEMOTHERAPY: SUMMARY AND CLOSING REMARKS;334
16.2.1;I. CHEMISTRY;334
16.2.2;II. PHARMACOKINETICS;334
16.2.3;III. TOXICITY;335
16.2.4;IV. ANTITUMOR ACTIVITY;335
16.2.5;V. FUTURE CONSIDERATIONS;336
16.2.6;VI. SUMMARY;337
16.2.7;REFERENCES;337